Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

PR Newswire09-13

To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467729870?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g5sTcvdlA7cWVdQn5C2Whg--~B/aD0xMTc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d5bff9013032d21692fda6af75e6daf2","is_english":true,"pubTime":"2024-09-13 19:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2467729870","market":"us","top_or_hot":-1,"title":"Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System","media":"PR Newswire","content":"<div>\n<p>To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device\nTargeting treatment for 20 million ICU patients with respiratory failure annually, with...</p>\n\n<a href=\"https://finance.yahoo.com/news/inspira-secures-second-u-patent-113000632.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/inspira-secures-second-u-patent-113000632.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device\nTargeting treatment for 20 million ICU patients with respiratory failure annually, with...</p>\n\n<a href=\"https://finance.yahoo.com/news/inspira-secures-second-u-patent-113000632.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IINNW","symbol_name":"Inspira Technologies Oxy BHN Ltd Warrant","start_time":0,"source_url":"https://finance.yahoo.com/news/inspira-secures-second-u-patent-113000632.html","article_id":"2467729870","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g5sTcvdlA7cWVdQn5C2Whg--~B/aD0xMTc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d5bff9013032d21692fda6af75e6daf2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inspira-secures-second-u-patent-113000632.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2467729870","pubTimestamp":1726227000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRAART device. Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry. RA'ANANA, Israel, Sept. 13, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd.  , a breakthrough medical technology company targeting to supersede mechanical ventilators, has secured an additional U.S. Patent approval for the VORTXorbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA ART device, bringing the combined total of claims deemed novel relating to the core technology of the INSPIRAART device, to 32.Dagi Ben-Noon, CEO of Inspira Technologies, remarked, \"We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA ART.\". The Company's INSPIRAART100 system","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IINNW":"Inspira Technologies Oxy BHN Ltd Warrant","IINN":"Inspira Technologies Oxy B.H.N. Ltd."},"translate_title":"Inspira™获得轨道血氧合输送系统第二项美国专利批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IINN":0.9,"IINNW":0.9},"content_text":"To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device\nTargeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry\nRA'ANANA, Israel, Sept. 13, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the \"Company\" or \"Inspira Technologies\"), a breakthrough medical technology company targeting to supersede mechanical ventilators, has secured an additional U.S. Patent approval for the VORTX™ orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART device, bringing the combined total of claims deemed novel relating to the core technology of the INSPIRA™ ART device, to 32.\n\n\n\nThe VORTX™ system aims to oxygenate blood without fiber membranes, potentially transforming the medical field as this technology is expected to reduce both blood damage and costs. Today's fiber technologies for blood oxygenation significantly harm the patient's blood cells, since existing fiber oxygenators force blood to flow through multiple fiber layers, causing harmful turbulence, friction, and shear forces. Due to the fiber fabric's high resistance to blood flow, it creates pressure differences that can severely damage blood components, potentially causing hemolysis, white blood cell damage, inflammatory and immune system activation, and blood clotting.\nDagi Ben-Noon, CEO of Inspira Technologies, remarked, \"We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA™ ART.\"\nWe believe the INSPIRA™ ART is a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. Designed to support the 20 million intensive care unit patients with respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA™ ART offers a potential alternative by maintaining stable oxygen saturation levels without the need for ventilators while patients can remain awake during treatment.\nInspira Technologies OXY B.H.N. Ltd.\nInspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), with adaptive blood monitoring and blood oxygenation technology designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. Equipped with HYLA™ real-time continuous blood monitoring technology, the system instantly detects changes in patient conditions, empowering physicians in making informed decisions.\nThe Company's INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in Cardiopulmonary Bypass procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.\nThe Company's other products, including the INSPIRA™ ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans and have not been approved by any regulatory entity.\nFor more information, please visit our corporate website: https://inspira-technologies.com.\nForward-Looking Statement Disclaimer\nThis press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses intended benefits and uses of its technology, the number of potential patients, and potential market size, that may utilize its technology and products, the belief that the patent is a major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA and the belief that the INSPIRA ART is an innovative device set to transform the $19 billion mechanical ventilation industry. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading \"Risk Factors\" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the \"SEC\"), which is available on the SEC's website, www.sec.gov.\nMRK-ARS-116\nCopyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All rights reserved.\nLogo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg\nFor more details: Inspira Technologies – Media RelationsEmail: info@inspirao2.comPhone: +972-9-9664485\n View original content:https://www.prnewswire.com/news-releases/inspira-secures-a-second-us-patent-approval-for-orbiting-blood-oxygenation-delivery-system-302247625.html\nSOURCE Inspira Technologies","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467729870"}